If I choose to go in that direction — when I say I, it’s me, it’s our management team, it’s our Board of Directors. We’re going to have lots of options on what to do. I focused on Pharmaloz first because this isn’t even what I’m excited about, but it gives you an idea of the risk/reward of investing in our company that if we have one asset here that I believe is potentially worth more than the entire market value of the company in the coming months and potentially could be worth double the market cap of our company if we keep it for a year or year-and-a-half, and we got these major lozenges brands, we have executive lining from around the world just to meet in Lebanon, Pennsylvania. It’s really exciting what we’re doing there. So, I’ll leave it at that for Pharmaloz.
I want to give you that as the background, so when we talk about Nebula Genomics and our BE-Smart cancer test and Equivir, these have enormous potential going forward, but the beauty is you have this tremendous asset value protecting your downside risk, which, in some cases, the most important thing when you invest in microcap companies. So with that, let’s get into Nebula a little bit. Founded by George Church, critically important because he’s been world renowned in the field of genomics for 15 or 20 years, and he has relationships with every — virtually every major global player in the field of genomics. He has introduced us to so many major players that we are collaborating with. It truly helps us in building Nebula Genomics. I’m going to get into some details about at the moment.
I’ll just tell you, he is such a big believer in Nebula. He had a choice of cashing out, taking cash when we acquired the company as a co-founder, and instead, he chose to take stock at about $7.50 a share. The reason why whole genome sequencing has become so exciting now is because the prices dropped dramatically. All the ancestry companies historically had to do the SNP-based testing where they analyze less than 1% of your data. They had to do that because whole genome sequencing is too expensive. If it’s even $1,000 for whole genome sequencing, in order to make a profit between the lab and their markup to consumers, they would have to charge $2,000. Nobody in $2,000 for an ancestry test. But now pricing has come down. So, while the ancestry companies build a whole platform on a different type of test, we can now provide whole genome sequencing with tremendous in-depth health insights in addition to ancestry test, and we are now getting to a point where we’re going to be able to provide a competitive product to the ancestry test, while giving phenomenally more data about your health.
So, it’s a really exciting opportunity. It’s been a work in progress. You’re going to see the fruits of our labor play out over this year now that we’re getting into the B2B business. I just want to explain a little bit more about it, and then I’ll talk about the opportunities in the B2B world and why we’re going in the direction we’re going in. Just to explain, in addition to ancestry, we provide in health. First of all, we have an incredible database, which has an amazing hidden asset value. It is a gem that I will be talking to you further about in the coming weeks, not for this call. But understand if an ancestry database studying less than 1% of your DNA is valuable, just imagine whole genome sequencing which studies virtually 100%, greater than 99% of your DNA, providing between 1,000 and 5,000 times more data points than an ancestry test.
Imagine what our database could be worth. So, I hope to update you in the coming weeks on that. But so understand, we also built a proprietary reporting system of bioinformatics based on this tremendous database that we’ve already built. We don’t know of any other bioinformatics in the world that compare to ours. So, we have these B2B businesses that are all over us for a number of reasons, including our reporting. So this is an idea. These are two of our reports I gave one example, I changed up the examples, gastroesophageal reflux disease, GERD. GERD leads to esophageal cancer. GERD is the first step. It’s acid in your stomach, it eats away at the bottom of your stomach. It can create cancerous cells, precancerous cells. That’s a condition known as Barrett’s esophagus.
One in 50 to one in 100 people can develop esophageal cancer. I’m going to get more into that when we talk about our cancer test that we’re developing. But the bottom line is if you know you’re at high risk, like this person in this example is in the 92nd percentile, you might want to go to your GI more often. You might want to really check on that acid in your stomach and not just take TUMS for it. And you might want to get an endoscopy once in a while if you’re at high risk, because with an endoscopy hopefully you can learn if you have esophageal cancer at an earlier stage and hopefully save your life. So that’s just one example knowing that you’re at high risk based on your DNA makeup. Another example, if based on your genetic makeup, you’re at high risk of breast cancer, you’re going to be motivated to get your checkups much more often, or colon cancer, you’ll get colonoscopies more often and at an earlier age.
